The purpose of the study was to determine the age at which initiation of specific subcutaneous immunotherapy (SCIT) becomes more cost-effective than continued lifetime intranasal steroid (NS) therapy in the treatment of allergic rhinitis, with the use of a decision analysis model.
Methods
A Markov decision analysis model was created for this study. Economic analyses were performed to identify “break-even” points in the treatment of allergic rhinitis with the use of SCIT and NS. Efficacy rates for therapy and cost data were collected from the published literature. Models in which there was only incomplete improvement while receiving SCIT were also evaluated for economic break-even points. The primary perspective of the study was societal.
Results
Multiple break-even point curves were obtained corresponding to various clinical scenarios. For patients with seasonal allergic rhinitis requiring NS (i.e., fluticasone) 6 months per year, the age at which initiation of SCIT provides long-term direct cost advantage is less than 41 years. For patients with perennial rhinitis symptoms requiring year-round NS, the cut-off age for SCIT cost-effectiveness increases to 60 years. Hypothetical subjects who require continued NS treatment (50% reduction of previous dosage) while receiving SCIT also display break-even points, whereby it is economically advantageous to consider allergy referral and SCIT, dependent on the cost of the NS prescribed.
Conclusion
The age at which SCIT provides economic advantages over NS in the treatment of allergic rhinitis depends on multiple clinical factors. Decision analysis models can assist the physician in accounting for these factors and customize patient counseling with regard to treatment options.
Get full access to this article
View all access options for this article.
References
1.
AlkireM.Driving out waste in health care.J Healthcare Financial Management Assoc66: 108–109, 2012.
2.
CauchiR., HinkleyK., and YondorfB.Great ideas for cutting costs: Six more strategies to manage the rising costs of health care.State Legislatures38: 28–31, 2012.
3.
GorollA.H., and SchoenbaumS.C.Payment reform for primary care within the accountable care organization: A critical issue for health system reform.JAMA308: 577–578, 2012.
4.
HolahanJ., and McMorrowS.Medicare and Medicaid spending trends and the deficit debate.N Engl J Med367: 393–395, 2012.
5.
RoehrigC., TurnerA., Hughes-CromwickP., and MillerG.When the cost curve bent: Pre-recession moderation in health care spending.N Engl J Med367: 590–593, 2012.
6.
BlanchetteC.M., DalalA.A., and MapelD.Changes in COPD demographics and costs over 20 years.J Med Econ15: 1176–1182, 2012.
7.
GheorghianA., SchnitzlerM.A., AxelrodD.A.The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation.Transplantation94: 241–249, 2012.
8.
HoffmannU., TruongQ.A., SchoenfeldD.A.Coronary CT angiography versus standard evaluation in acute chest pain.N Engl J Med367: 299–308, 2012.
9.
PollockR., MudumaG., and ValentineW.Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.Diabetes Obes Metab15: 121–129, 2013.
10.
CavanaughT.M., BuringS., and CluxtonR.A pharmacoeconomics and formulary management collaborative project to teach decision analysis principles.Am J Pharmaceut Educ76: 115, 2012.
11.
DiamantopoulosA., SawyerL., OgaleS., and DejonckheereF.Validity of cost and utility results?Pharmacoeconomics30: 977, 2012.
12.
van LuijnJ.C.Is There a role for pharmacoeconomics in decision making?Pharmacoeconomics30: 979, 2012.
GerzeliS., RognoniC., QuagliniS.Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.Clin Drug Investig32: 253–265, 2012.
15.
HockenhullJ., ElremeliM., CherryM.G.A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen(R) for the treatment of bee and wasp venom allergy.Health Technol Assess16: III–IV, 1–110, 2012.
16.
ArianoR., BertoP., TracciD.Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma.Allergy Asthma Proc27: 159–163, 2006.
17.
BrüggenjürgenB, ReinholdT., BrehlerR.Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.Ann Allergy Asthma Immunol101: 316–324, 2008.
18.
OmnesL.F., BousquetJ., ScheinmannP.Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France.Eur Ann Allergy Clin Immunol39: 148–156, 2007.
19.
PetersenK.D., Gyrd-HansenD., DahlR.Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy.Allergologia et Immunopathologia33: 296–302, 2005.
20.
PokladnikovaJ., KrcmovaI., VlcekJ.Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.Ann Allergy Asthma Immunol100: 482–489, 2008.
21.
LockeyR.F., HankinC.S.Health economics of allergen-specific immunotherapy in the United States.J Allergy Clin Immunol127: 39–43, 2011.
22.
BernsteinJ.A.Pharmacoeconomic considerations for allergen immunotherapy.Clin Allergy Immunol18: 151–164, 2004.
23.
DonahueJ.G., GreinederD.K., Connor-LackeL.Utilization and cost of immunotherapy for allergic asthma and rhinitis.Ann Allergy Asthma Immunol82: 339–347, 1999.
24.
HankinC.S., CoxL., LangD.Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study.Ann Allergy Asthma Immunol104: 79–85, 2010.
25.
HankinC.S., CoxL., LangD.Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs.J Allergy Clin Immunol121: 227–232, 2008.
26.
MattosJ.L., WoodardC.R., and PayneS.C.Trends in common rhino-logic illnesses: Analysis of US healthcare surveys 1995–2007.Int Forum Allergy Rhinol1: 3–12, 2011.
27.
BlaissM.S.Allergic rhinitis: Direct and indirect costs.Allergy Asthma Proc31: 375–380, 2010.
28.
WallaceD.V., DykewiczM.S., BernsteinD.I.The diagnosis and management of rhinitis: An updated practice parameter.J Allergy Clin Immunol122: S1–S84, 2008.
29.
DykewiczM.S., KaiserH.B., NathanR.A.Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn).Ann Allergy Asthma Immunol91: 44–48, 2003.
30.
JenA., BaroodyF., de TineoM.As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis.J Allergy Clin Immunol105: 732–738, 2000.
31.
KaszubaS.M., BaroodyF.M., deTineoM.Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.Arch Intern Med161: 2581–2587, 2001.
MosbechH., and OsterballeO.Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis.Allergy43: 523–529, 1988.
36.
GeorgyM.S., and SaltounC.A.Chapter 3: Allergen immunotherapy: definition, indication, and reactions.Allergy Asthma Proc33(suppl 1): S9–S11, 2012.
37.
Larenas LinnemannD.E.One hundred years of immunotherapy: Review of the first landmark studies.Allergy Asthma Proc33: 122–128, 2012.
38.
ArbesS.J.Jr., GergenP.J., ElliottL., and ZeldinD.C.Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey.J Allergy Clin Immunol116: 377–383, 2005.
39.
RossR.N., NelsonH.S., and FinegoldI.Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: An analysis of randomized, prospective, single- or double-blind, placebo-controlled studies.Clin Therapeut22: 342–350, 2000.
40.
SchillerJ.S., LucasJ.W., WardB.W., and PeregoryJ.A.Summary health statistics for US adults: National Health Survey, 2010.Vital Health Stat10: 1–207, 2012.
41.
BernsteinI.L., StormsW.W.Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology.Ann Allergy Asthma Immunol75: 543–625, 1995.
42.
EngP.A., ReinholdM., GnehmH.P.Long-term efficacy of preseasonal grass pollen immunotherapy in children.Allergy57: 306–312, 2002.
43.
HedlinG., HeilbornH., LiljaG.Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy.J Allergy Clin Immunol96: 879–885, 1995.
44.
JacobsenL., NũchelPetersenB., WihlJ.A.Immunotherapy with partially purified and standardized tree pollen extracts, IV: Results from long-term (6-year) follow-up.Allergy52: 914–920, 1997.
45.
Di RienzoV., MarcucciF., PuccinelliP.Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.Clin Exp Allergy33: 206–210, 2003.
46.
CoxL., NelsonH., LockeyR.Allergen immunotherapy: A practice parameter third update.J Allergy Clinical Immunol127: S1–S55, 2011.
